采用 454 深度测序技术检测依曲韦林存在时多种非核苷类逆转录酶耐药 HIV-1 变异体的复制适应性。
Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing.
机构信息
BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
出版信息
J Virol. 2013 Aug;87(15):8805-7. doi: 10.1128/JVI.00335-13. Epub 2013 May 29.
Abstract
We applied an efficient method to characterize the relative fitness levels of multiple nonnucleoside reverse transcriptase (NNRTI)-resistant HIV-1 variants by simultaneous competitive culture and 454 deep sequencing. Using this method, we show that the Y181V mutation in the HIV-1 reverse transcriptase in particular confers a clear selective advantage to the virus over 14 other NNRTI resistance mutations in the presence of etravirine in vitro.
摘要
我们应用一种有效的方法，通过同时竞争培养和 454 深度测序来描述多种非核苷类逆转录酶抑制剂（NNRTI）耐药 HIV-1 变异体的相对适应性水平。使用这种方法，我们表明 HIV-1 逆转录酶中的 Y181V 突变，特别是在体外存在依曲韦林的情况下，赋予病毒相对于其他 14 种 NNRTI 耐药突变明显的选择优势。
相似文献
1
Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing.采用 454 深度测序技术检测依曲韦林存在时多种非核苷类逆转录酶耐药 HIV-1 变异体的复制适应性。
J Virol. 2013 Aug;87(15):8805-7. doi: 10.1128/JVI.00335-13. Epub 2013 May 29.
2
Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.HIV-1 逆转录酶位置 E138 突变及其与 M184I 突变的相互作用对定义非核苷类逆转录酶抑制剂利匹韦林和依曲韦林耐药模式的影响。
Antimicrob Agents Chemother. 2013 Jul;57(7):3100-9. doi: 10.1128/AAC.00348-13. Epub 2013 Apr 22.
3
Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.与原发性感染期间 HIV-1 非核苷类逆转录酶抑制剂耐药相关的少数变异体。
J Clin Virol. 2012 Oct;55(2):107-13. doi: 10.1016/j.jcv.2012.06.018. Epub 2012 Jul 20.
4
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.人类免疫缺陷病毒 1 型逆转录酶中的 V106I 和 V179D 多态性突变的组合赋予了对依非韦伦和奈韦拉平的耐药性，但对埃替拉韦则没有。
Antimicrob Agents Chemother. 2010 Apr;54(4):1596-602. doi: 10.1128/AAC.01480-09. Epub 2010 Feb 1.
5
Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.逆转录酶（RT）突变体与拉米夫定和依曲韦林耐药性的相互作用：对人类免疫缺陷病毒 1 型的适应性和 RT 活性的影响。
J Virol. 2011 Nov;85(21):11309-14. doi: 10.1128/JVI.05578-11. Epub 2011 Aug 17.
6
The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.HIV-1 逆转录酶中的连接域突变 N348I 增强了对依曲韦林和利匹韦林的耐药性，但通过降低病毒复制能力限制了 E138K 耐药突变的出现。
J Virol. 2014 Feb;88(3):1536-47. doi: 10.1128/JVI.02904-13. Epub 2013 Nov 13.
7
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.非核苷类逆转录酶抑制剂耐药的 HIV 在感染早期受到依非韦伦的刺激。
J Virol. 2011 Oct;85(20):10861-73. doi: 10.1128/JVI.05116-11. Epub 2011 Aug 10.
8
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.HIV-1 逆转录酶连接域突变不会影响依曲韦林的敏感性和依曲韦林含药方案的病毒学应答。
Antimicrob Agents Chemother. 2011 Jun;55(6):2872-9. doi: 10.1128/AAC.01695-10. Epub 2011 Apr 4.
9
Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.HIV-1 非核苷类逆转录酶抑制剂突变 K103N 和 M230L 对病毒复制和酶功能的差异影响。
J Antimicrob Chemother. 2010 Nov;65(11):2291-9. doi: 10.1093/jac/dkq338. Epub 2010 Sep 18.
10
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.耐奈韦拉平、依非韦伦、埃替拉韦和利匹韦林的原型重组传染性分子克隆耐药性面板。
Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.
引用本文的文献
1
Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.HIV-1 逆转录酶中 181 位氨基酸突变导致非核苷类逆转录酶抑制剂高敏性和耐药性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00676-19. Print 2019 Aug.
2
High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.早期猿猴免疫缺陷病毒感染期间病毒群体的高分辨率测序揭示了快速逃避新出现的Env特异性抗体反应的进化策略。
J Virol. 2018 Mar 14;92(7). doi: 10.1128/JVI.01574-17. Print 2018 Apr 1.
3
Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.非核苷类逆转录酶抑制剂耐药突变对HIV-1 B亚型和A/E亚型感染中细胞毒性T淋巴细胞识别的不同影响
J Virol. 2015 Jul;89(14):7363-72. doi: 10.1128/JVI.00974-15. Epub 2015 May 13.
4
Deep sequencing: becoming a critical tool in clinical virology.深度测序：成为临床病毒学中的关键工具。
J Clin Virol. 2014 Sep;61(1):9-19. doi: 10.1016/j.jcv.2014.06.013. Epub 2014 Jun 24.
5
Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine.竞争性适应性检测表明，HIV-1逆转录酶中的E138A替代降低了体外对恩曲他滨的敏感性。
Antimicrob Agents Chemother. 2014;58(4):2430-3. doi: 10.1128/AAC.02114-13. Epub 2014 Jan 13.
本文引用的文献
1
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.依曲韦林耐药性分析：来自随机、对照 III 期临床研究的基线基因型和表型数据的综合分析。
AIDS. 2010 Feb 20;24(4):503-14. doi: 10.1097/QAD.0b013e32833677ac.
2
Clinical significance of human immunodeficiency virus type 1 replication fitness.1型人类免疫缺陷病毒复制适应性的临床意义
Clin Microbiol Rev. 2007 Oct;20(4):550-78. doi: 10.1128/CMR.00017-07.
3
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.TMC125（依曲韦林）在DUET - 2研究中经治HIV - 1感染患者中的疗效与安全性：一项随机、双盲、安慰剂对照试验的24周结果
Lancet. 2007 Jul 7;370(9581):39-48. doi: 10.1016/S0140-6736(07)61048-4.
4
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.TMC125，一种新型的下一代非核苷类逆转录酶抑制剂，对耐非核苷类逆转录酶抑制剂的1型人类免疫缺陷病毒具有活性。
Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6. doi: 10.1128/AAC.48.12.4680-4686.2004.
5
A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.一种用于快速体内分析1型人类免疫缺陷病毒对逆转录酶抑制剂敏感性的重组逆转录病毒系统。
Antimicrob Agents Chemother. 1997 Dec;41(12):2781-5. doi: 10.1128/AAC.41.12.2781.
Zotero 插件